Academic-community partnerships can reduce patient travel burdens while maintaining high-quality cancer care, as demonstrated by successful high-dose cytarabine consolidation delivery. A flow ...
AML 3.0 by IDMERIT is redefining what modern anti money laundering software looks like - faster screening, smarter monitoring ...
– Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Final Analysis Planned Upon Reaching 80 ...
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel ...
RegTech platform AML Watcher expands its agentic AML screening stack with TruRisk, now handling the investigative workload that traditional AML case management software leaves to human analysts.
CERo Therapeutics received FDA approval for its IND CMC amendment, crucial for starting CER-1236 patient dosing. The phase 1 trial will assess CER-1236's safety and efficacy in relapsed or refractory ...
SELLAS Life Sciences Group, Inc. has announced significant milestones in its clinical development of cancer therapies. An Independent Data Monitoring Committee will conduct an interim analysis of the ...
The classification of AML and therapeutic options are now largely driven by genetically defined subtypes. Personalization of treatment relies on timely completion and reporting of cytogenetic and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results